摘要目的 观察解氏肺癌1号方治疗晚期非小细胞肺癌患者的临床疗效、对免疫功能、血清血管内皮生长因子(VEGF)、角质蛋白21-1(CYFRA21-1)的影响.方法 将650例晚期非小细胞肺癌患者按随机数字表法分为治疗组350例和化疗组300例,治疗组口服解氏肺癌1号方,对照组采用GP方案或TP方案化疗,两组均治疗1个月为1个疗程,2个疗程后进行疗效评定.结果 治疗组肿瘤近期治疗有效率为56.57%,优于化疗组的44.33%(P<0.01);治疗组KPS评分提高稳定率为85.14%,高于对照组的27.08%(JP<0.01);T细胞总数、辅助性T细胞及NK细胞水平均高于化疗组,抑制性T细胞水平及VEGF、CYFRA21.1水平均低于对照组.远期疗效观察,对其中2005年117例晚期非小细胞肺癌患者进行观察,治疗组生存时间1年以上存活率83.59%,3年以上存活率46.27%,分别与对照组的1年、3年的存活率比较,差异有统计学意义(P<0.01).结论 解氏肺癌1号方可延长非小细胞肺癌患者生存时间,改善生活质量,增强免疫功能,抑制肿瘤细胞的活动.

abstractsObjective To observe the clinical effects of Xie's Feiai No.1 formula on patients with advanced non-small cell lung cancer (NSCLC) and its influence on body immune system, VEGF (blood vessel endothelia growth factor) and CYFRA21-1 (keratoprotein 21-1). Methods 650 cases of advanced NSCLC were randomized into a treatment group and chemotherapy group, with 350 cases and 300 cases in each group respectively. The treatment group was administrated with Xie's Feiai No.1 formula, while the chemotherapy group was treated with chemotherapy ofGP plan/TP plan. Both groups were treated for 2 months. Results The short-term effective rate was 56.57% in the treatment group, which was superior to 44.33% (P<0.01) in the chemotherapy group; Steady rate KPS score improvement was 85.14% in the treatment group, which was also higher than 27.00% (P<0.01) in the chemotherapy group; besides the levels of total T cell, adjuvant T cell and NK cell in the treatment group were higher than the chemotherapy group, while the levels of Ts cell, VEGF and CYFRA21-1 int the treatment group were lower than the chemotherapy group. Long-term efficacy observation showed that the survival rate of 117 cases with advanced NSCLC was 83.59% in one year and 46.27% in three years in the treatment group, both significantly higher than those in the chemotherapy group (P<0.01).Conclusion Xie's Feiai No.l formula can increase NSCLC patients' survival time, improve quality of life, strengthen immunological function and restrain tumor cells' activities.